Long-term efficacy of dapagliflozin in type 2 diabetes

In this study, conducted between 2015 and 2020, the long-term efficacy of dapagliflozin on renal function and albuminuria in type 2 diabetic patients was evaluated. Study endpoints were changes in glomerular filtration rate, changes in albuminuria and changes in renal function. Patients in the non-dapagliflozin group were treated with DPP-4 inhibitors, GLP-1 analogues, hypoglycemic sulfonamides, pioglitazone, metformin or acarbose. Albuminuria decreased significantly within 6 months of initiation of dapagliflozin. Patients on dapagliflozin had significantly lower rates of new-onset chronic kidney disease.